fashion -WSS

fashion

author：Wikipedia 2025-09-02 08:21:42 - browse：975

Jakub Porzycki/NurPhoto via AP

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hello, everyone. Damian here with the fallout from Pfizer’s downbeat update, a new entrant in obesity research, and an orthogonal CRISPR business.

The need-to-know this morning

Apellis Pharmaceuticals said a European advisory committee is expected to recommend against the approval of Syfovre, its eye drug for a common form of blindness. The company plans to appeal the negative ruling.
Sage Therapeutics and Biogen announced the commercial launch of Zurzuvae, an oral treatment for women with postpartum depression.
Merck and Moderna reported three-year follow-up data on their mRNA-based immunotherapy for advanced melanoma. Phase 3 studies are underway.
The FDA accepted Amgen’s marketing application for tarlatamab, a bispecific antibody to treat advanced small cell lung cancer. The approval decision date is June 12, 2024.

Is it time to worry about Moderna?

Yesterday’s news that Pfizer is expecting to sell far fewer Covid-19 vaccines than Wall Street expected sent shares of Moderna down as much as 6% on fears that the company could be in for a painful revision of its own.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： RaDonda Vaught to speak at CommonSpirit event on patient safety

WSS

Patients, doctors press FTC to beef up hospital merger scrutiny

Free Covid tests will again be offered to all U.S. households

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

Patients, doctors press FTC to beef up hospital merger scrutiny

David Liu startup to focus on CRISPR delivery

International team creates first chimeric human

hotspot

fashion

The need-to-know this morning

Is it time to worry about Moderna?

explore

ChatGPT in medicine: STAT answers readers' burning questions

ALS groups 'won't be played again' by the FDA, drug sponsors

Jerome Adams on the need for new antivirals for Covid

Why the quest to eradicate polio has stumbled

Affirmative action in medical school literally saved lives

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

In Memoriam: Notable people who died in 2023

Patients, doctors press FTC to beef up hospital merger scrutiny

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Congress gives doctors Medicare pay bump

hotspot

People with substance use disorder deserve online privacy

Fed up with FDA, ALS advocates consider a take

Biotech companies concerned about China biosecurity crackdown

Fed up with FDA, ALS advocates consider a take

PBMs drew scrutiny in House hearing — and so did pharma

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

hotspot

focus

hotspot

focus